A Pilot Study of a Remote ADHD Monitoring Program (NCT06743425)
A Pilot Study of a Remote Attention-Deficit/Hyperactivity Disorder Monitoring Program (RAMP) for Children in Rural Areas
🩺 Plain-English Summary (8th-Grade Level)
RAMP is a pilot study examining the use of an Attention-Deficit/Hyperactivity Disorder (ADHD) Monitoring Program during the early stages of treating ADHD in children living in rural settings. This trial will enroll 36 caregiver/infant dyads across 2 sites and will evaluate feasibility endpoints rather than clinical outcomes. Enrolled participants will be randomized 1:1 to the intervention group (RAMP reports) or control group (digital education handouts). The study duration is 10 months, including start-up, enrollment and intervention, and data analysis and manuscript submission.
Who can join: Review the eligibility criteria below.
Location: University of Mississippi Medical Center — Jackson, Mississippi
Age range: 5 Years to 11 Years
🧪 Interventions in This Study
- RAMP Reports (OTHER)
- Digital Education Handouts (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (2 Sites)
- University of Mississippi Medical Center — Jackson, Mississippi
- Medical University of South Carolina — Charleston, South Carolina
📞 Contact the Study Coordinator
Phone: (501) 686-7233
Email: STOunpraseuth@uams.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Attention-deficit/Hyperactivity Disorder
- Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) — Little Rock, Arkansas
- An Open-Label Treatment With Randomization Observation, Investigator-Initiated Study, on the Duration and Efficacy of Jornay PM (Methylphenidate Hydrochloride Extended-Release Capsules) on Adult ADHD Symptoms and Executive Function and Emotional Regulation Throughout the Day Into Early Evening — New York, New York
- The Effects of Cannabigerol on Attention-Deficit/Hyperactivity Disorder — Fayetteville, Arkansas
- Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD — Saraland, Alabama
Explore by condition: All Attention-deficit/Hyperactivity Disorder clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.